Home > Riviste > Italian Journal of Dermatology and Venereology > Fascicoli precedenti > Italian Journal of Dermatology and Venereology 2021 October;156(5) > Italian Journal of Dermatology and Venereology 2021 October;156(5):534-44

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi PROMO
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

REVIEW   Freefree

Italian Journal of Dermatology and Venereology 2021 October;156(5):534-44

DOI: 10.23736/S2784-8671.20.06606-7

Copyright © 2020 EDIZIONI MINERVA MEDICA

lingua: Inglese

How do we treat cutaneous T-cell lymphoma?

René STRANZENBACH

Department of Dermatology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany



Cutaneous T-cell lymphomas are a heterogeneous group of non-Hodgkin lymphomas which are based on the malignant proliferation of skin-related T lymphocytes. The clinical appearance, as well as the course and the associated therapeutic approach, are sometimes very different between the different subtypes. Since allogeneic stem cell transplantation is currently the only curative option, and the morbidity and mortality are not insignificant, a therapy concept should be developed that considers its often rather indolent but chronic course. This concept should enable a good disease control with as few side effects as possible and preserve or improve the quality of life. In the early stages of the disease, skin-oriented therapies are generally used first before systemic and increasingly aggressive therapeutic agents are used as the disease progresses. Considering the current guidelines, literature and subjective experience, we summarize in this review how we treat cutaneous T-cell lymphomas.


KEY WORDS: Lymphoma, T-cell, cutaneous; T-lymphocytes; Mycosis fungoides

inizio pagina